Inogen, Inc. (NASDAQ:INGN) Shares Purchased by State Street Corp

State Street Corp grew its stake in shares of Inogen, Inc. (NASDAQ:INGN) by 2.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 511,018 shares of the medical technology company’s stock after purchasing an additional 14,054 shares during the quarter. State Street Corp owned 2.15% of Inogen worth $4,957,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Meeder Asset Management Inc. acquired a new position in Inogen during the 2nd quarter worth approximately $30,000. Quarry LP purchased a new stake in shares of Inogen during the third quarter valued at approximately $59,000. Verition Fund Management LLC acquired a new position in shares of Inogen during the third quarter worth $106,000. Paloma Partners Management Co purchased a new position in shares of Inogen in the third quarter valued at $126,000. Finally, Centiva Capital LP acquired a new stake in Inogen during the 3rd quarter valued at $138,000. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Friday, November 8th. StockNews.com cut Inogen from a “buy” rating to a “hold” rating in a research note on Friday, December 20th.

Inogen Trading Down 0.2 %

Shares of NASDAQ:INGN opened at $8.58 on Monday. Inogen, Inc. has a 12-month low of $5.08 and a 12-month high of $13.33. The firm has a market cap of $204.38 million, a PE ratio of -3.81 and a beta of 1.02. The company has a fifty day simple moving average of $9.38 and a 200 day simple moving average of $9.74.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.